Interpace Biosciences, Inc. (IDXG)
OTCMKTS · Delayed Price · Currency is USD
1.998
+0.003 (0.13%)
Apr 22, 2026, 1:25 PM EST

Interpace Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
24.586.71.95-21.96-14.94
Depreciation & Amortization
0.820.751.63.55.37
Other Amortization
0.06-0.040.060.12
Loss (Gain) From Sale of Assets
----0.070.06
Asset Writedown & Restructuring Costs
0.2--12.4-
Stock-Based Compensation
0.040.290.631.31.37
Provision & Write-off of Bad Debts
-----0.14
Other Operating Activities
-21.140.580.81.070.57
Change in Accounts Receivable
2.9-3.470.23-0.132.15
Change in Accounts Payable
-0.810.120.49-0.74-1.82
Change in Other Net Operating Assets
-0.8-0.33-1.95-3.12-1.46
Operating Cash Flow
5.834.653.79-7.69-8.72
Operating Cash Flow Growth
25.51%22.62%---
Capital Expenditures
-0.36-0.88-0.47-0.32-0.35
Sale of Property, Plant & Equipment
----0.04
Other Investing Activities
--0.386.53-
Investing Cash Flow
-0.36-0.88-0.096.21-0.32
Short-Term Debt Issued
---27.5
Long-Term Debt Issued
---19.5
Total Debt Issued
---317
Short-Term Debt Repaid
-----7.92
Long-Term Debt Repaid
-4.4-5.6-2.5--
Total Debt Repaid
-4.4-5.6-2.5--7.92
Net Debt Issued (Repaid)
-4.4-5.6-2.539.08
Issuance of Common Stock
---0.110.34
Repurchase of Common Stock
-0.02-0.05-0.03-0.11-
Other Financing Activities
-0.01-0.16-2.5--0.44
Financing Cash Flow
-4.43-5.81-5.0338.98
Net Cash Flow
1.04-2.04-1.331.51-0.06
Free Cash Flow
5.483.773.32-8.01-9.07
Free Cash Flow Growth
45.23%13.59%---
Free Cash Flow Margin
14.14%8.03%8.29%-25.17%-27.40%
Free Cash Flow Per Share
0.200.240.76-1.89-2.19
Cash Interest Paid
0.170.631.090.970.42
Cash Income Tax Paid
0.10.010.270.250.37
Levered Free Cash Flow
5.091.41-1.19-0.031.78
Unlevered Free Cash Flow
5.141.82-0.60.542.31
Change in Working Capital
1.29-3.68-1.24-3.99-1.13
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.